Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-006661
Filing Date
2024-02-14
Accepted
2024-02-14 16:06:25
Documents
93
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1308510
2 ex31-1.htm EX-31.1 20700
3 ex31-2.htm EX-31.2 20284
4 ex32-1.htm EX-32.1 7993
5 ex32-2.htm EX-32.2 7872
  Complete submission text file 0001493152-24-006661.txt   7721639

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE eltp-20231231.xsd EX-101.SCH 61966
7 XBRL CALCULATION FILE eltp-20231231_cal.xml EX-101.CAL 81526
8 XBRL DEFINITION FILE eltp-20231231_def.xml EX-101.DEF 240478
9 XBRL LABEL FILE eltp-20231231_lab.xml EX-101.LAB 524633
10 XBRL PRESENTATION FILE eltp-20231231_pre.xml EX-101.PRE 421637
94 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1234245
Mailing Address 165 LUDLOW AVENUE NORTHVALE NJ 07647
Business Address 165 LUDLOW AVENUE NORTHVALE NJ 07647 2017502646
ELITE PHARMACEUTICALS INC /NV/ (Filer) CIK: 0001053369 (see all company filings)

EIN.: 223542636 | State of Incorp.: NJ | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 001-15697 | Film No.: 24637895
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)